Guidance

Influenza: antiviral susceptibility surveillance and diagnosis of resistance

Summarises incidence and mechanisms of NAI resistance in seasonal influenza viruses and availability of NAI susceptibility testing in UK.

• From: Public Health England
• Published: 17 October 2011
• Last updated: 20 November 2018 — See all updates

Documents

Surveillance and laboratory testing of influenza neuraminidase inhibitor resistance

Ref: PHE publications gateway number: 2018625

PDF, 380 KB, 15 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This information is for laboratory scientists, clinicians and public health practitioners with responsibility for:

• influenza virus diagnostic testing
• the management of patients receiving neuraminidase inhibitor (NAI) prophylaxis
• treatment or investigation of influenza virus outbreaks

Published 17 October 2011
Last updated 20 November 2018 + show all updates

1. 20 November 2018

   Replaced 2016 document with a revised version.

2. 2 December 2016

   Updated with latest guidance.

3. 17 October 2011

   First published.